← Human Trials & Peer-Reviewed Studies
Effect of Teriparatide on Bone Remodeling and Density in Premenopausal Idiopathic Osteoporosis: A Phase II Trial
Plain-language guide to PMID 32876328 (2020): placebo-controlled randomized controlled trial study of Teriparatide in 41 women, osteoporosis and bone density.
Key Facts
- PMID
- 32876328
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2020
- Study type
- Randomized Controlled Trial
- Authors
- Cohen A et al. (15 authors)
- DOI
- 10.1210/clinem/dgaa489
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Teriparatide in the context of osteoporosis and bone density, published as a randomized controlled trial.
Compare 6 months (M) of teriparatide versus placebo on areal bone mineral density (aBMD) by dual-energy x-ray absorptiometry (DXA), bone turnover markers (BTMs) and BFR at 3M by quadruple-labeled transiliac biopsy.
Characterize 12M and 24M effects of teriparatide on aBMD and whether BTMs and BFR predict response.
Why It Was Studied
Premenopausal women with idiopathic osteoporosis (IOP) have abnormal skeletal microarchitecture and variable tissue-level bone formation rate (BFR).
Who Took Part
The abstract describes 41 women taking part.
By PubMed's age tags, the people studied were adults, women only.
How the Study Was Run
In design terms this was a randomized and placebo-controlled study.
The women were allocated by chance, so the Teriparatide group and the comparison group should start out alike.
Some women received a placebo instead of Teriparatide, giving a reference point.
6M phase 2 randomized controlled trial (RCT) followed by open extension.
After 6M, those on placebo switched to teriparatide for 24M; those on teriparatide continued for 18M.
What Was Measured
Premenopausal women with idiopathic osteoporosis (IOP) have abnormal skeletal microarchitecture and variable tissue-level bone formation rate (BFR).
PubMed files the paper under topics including Absorptiometry, Photon, Bone Density, Bone Density Conservation Agents, Bone Remodeling, Osteoporosis, Premenopause and Teriparatide.
The authors tagged it with the keywords bone biopsy, bone turnover markers and premenopausal osteoporosis.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Teriparatide in 41 women in people with osteoporosis and bone density.
Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2020 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Teriparatide compound page, Osteoporosis and bone density research.
Our Notes on the Compound
Teriparatide: A parathyroid hormone fragment, PTH(1-34), with human trials and approved-pen labeling; the research vial is not the approved pen.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.